ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cemdisiran

Also written as “Cemdisiran”, “Pozelimab + Cemdisiran” and “ALN-CC5”.

Its studies are mostly in Hemoglobinuria, Paroxysmal · Geographic Atrophy · Myasthenia Gravis · Glomerulonephritis, IGA · Atypical Hemolytic Uremic Syndrome, led by 2 companies.

Drug pageCemdisiran: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 27, 202110 company-led studies, 4 open or runningNext primary completion: Jul 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticalsits history only74 open or runningphase 3since Sep 27, 2021Oct 21, 2020Jul 31, 2028phase 3 · NCT06541704
Alnylam Pharmaceuticals30 open or runningphase 2since Jan 23, 2015Jan 23, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Alnylam Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 23, 2015First study: phase 2 study in Hemoglobinuria, ParoxysmalFirst studyNCT02352493 · 62 enrolled · Spain, United Kingdom
  2. Dec 9, 2015Named cemdisiranINNProposed as its International Nonproprietary Name in WHO's List 114
  3. Sep 25, 2017Phase 2 study in Atypical Hemolytic Uremic SyndromeNCT03303313 · Bosnia and Herzegovina, Canada, Estonia and more
  4. Feb 13, 2019Phase 2 study in Glomerulonephritis, IGANCT03841448 · 31 enrolled · Canada, France, Malaysia and more

TargetBeta

C5 →read by rule
“A proprietary formulation composed of small-interfering RNAs (siRNAs) directed against terminal complement component 5 (C5) of the complement pathway ”NCIt, by rule

Other programs on C5

ProgramCompanyFurthest phaseStudies
eculizumabruleAstraZenecaphase 438
ravulizumabruleAstraZenecaphase 435
pozelimabruleRegeneron Pharmaceuticalsphase 414
zilucoplanruleUCBphase 314
vilobelimabruleinflarx-gmbhphase 313
CrovalimabruleHoffmann-La Rochephase 310
ABBV-6628AbbViephase 21

Studies

All 3 Alnylam Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03841448Glomerulonephritis, IGA · Canada, France, Malaysia and more2TerminatedMar 17, 202231
NCT03303313Atypical Hemolytic Uremic Syndrome · Bosnia and Herzegovina, Canada, Estonia and more2WithdrawnSep 12, 20180
NCT02352493Hemoglobinuria, Paroxysmal · Spain, United Kingdom2CompletedApr 201662

How it is read

Names in the registry

  • “Cemdisiran”, 9 entries
  • “Pozelimab + Cemdisiran”, 1 entry
  • “ALN-CC5”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.